Price (delayed)
$13.87
Market cap
$985.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$934.5M
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of
There are no recent dividends present for ZYME.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.